Bedaquiline resistance: its emergence, mechanism, and prevention

TVA Nguyen, RM Anthony, AL Bañuls… - Clinical Infectious …, 2018 - academic.oup.com
Bedaquiline, a new antituberculosis drug, has already been used in> 50 countries. The
emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this …

Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems

AG Märtson, G Burch, S Ghimire… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Therapeutic drug monitoring (TDM) has been recommended for treatment
optimization in tuberculosis (TB) but is only is used in certain countries eg USA, Germany …

Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response

X Zheng, Z Bao, LD Forsman, Y Hu… - Clinical Infectious …, 2021 - academic.oup.com
Background Prospective studies correlating pharmacokinetic/pharmacodynamic (PK/PD)
indices to clinical responses are urgently needed. This study aimed to find clinically relevant …

Discovery and validation of a six-marker serum protein signature for the diagnosis of active pulmonary tuberculosis

MA De Groote, DG Sterling, T Hraha… - Journal of clinical …, 2017 - Am Soc Microbiol
New non-sputum biomarker tests for active tuberculosis (TB) diagnostics are of the highest
priority for global TB control. We performed in-depth proteomic analysis using the 4,000-plex …

A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs

A Daskapan, LR Idrus, MJ Postma, B Wilffert… - Clinical …, 2019 - Springer
Introduction Contrasting findings have been published regarding the effect of human
immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). Objectives …

[HTML][HTML] New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS

M Karaźniewicz-Łada, K Kosicka-Noworzyń… - … of Pharmaceutical and …, 2023 - Elsevier
Successful tuberculosis (TB) therapy requires achieving sufficient exposure to multiple
drugs. Limited stability of several first-line anti-TB drugs might compromise reliable …

[HTML][HTML] How to design a study to evaluate therapeutic drug monitoring in infectious diseases?

AG Märtson, MGG Sturkenboom, J Stojanova… - Clinical Microbiology …, 2020 - Elsevier
Background Therapeutic drug monitoring (TDM) is a tool to personalize and optimize dosing
by measuring the drug concentration and subsequently adjusting the dose to reach a target …

The role of therapeutic drug monitoring in mycobacterial infections

C Peloquin - Microbiology spectrum, 2017 - Am Soc Microbiol
Tuberculosis (TB) is a leading cause of infectious death. Nontuberculous mycobacteria
(NTM) cause a wide variety of difficult-to-treat infections in various human hosts. Therapeutic …

Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes

Y Xu, J Wu, S Liao, Z Sun - Annals of clinical microbiology and …, 2017 - Springer
Tuberculosis (TB) is considered as one of the most serious threats to public health in many
parts of the world. The threat is even more severe in the developing countries where there is …

Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring

SHJ van den Elsen, LM Oostenbrink… - Therapeutic drug …, 2018 - journals.lww.com
Background: Therapeutic drug monitoring is useful in the treatment of tuberculosis to assure
adequate exposure, minimize antibiotic resistance, and reduce toxicity. Salivary therapeutic …